The latest price target for CRISPR Therapeutics (NASDAQ:CRSP) was reported by RBC Capital on November 6, 2024. The analyst firm set a price target for $53.00 expecting CRSP to rise to within 12 months (a possible 13.28% upside). 42 analyst firms have reported ratings in the last year.

The latest analyst rating for CRISPR Therapeutics (NASDAQ:CRSP) was provided by RBC Capital, and CRISPR Therapeutics reiterated their sector perform rating.

The last upgrade for CRISPR Therapeutics AG happened on August 18, 2023 when Citigroup raised their price target to $70. Citigroup previously had a neutral for CRISPR Therapeutics AG.

The last downgrade for CRISPR Therapeutics AG happened on December 11, 2023 when TD Cowen changed their price target from N/A to $30 for CRISPR Therapeutics AG.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CRISPR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CRISPR Therapeutics was filed on November 6, 2024 so you should expect the next rating to be made available sometime around November 6, 2025.

While ratings are subjective and will change, the latest CRISPR Therapeutics (CRSP) rating was a reiterated with a price target of $53.00 to $53.00. The current price CRISPR Therapeutics (CRSP) is trading at is $46.79, which is out of the analyst’s predicted range.